Cambridge Cognition Holdings (LSE:COG) has been busy in the autumn, announcing a Partnership with C2N Diagnostics and The Alzheimer's Trust on 21 September 2026 and joining an Imperial College-led NHS study on 6 October. The moves came alongside interim results showing Revenue growth of 16% and a narrower loss. For investors in the FTSE AIM All Share Index, the company is a small-cap digital health name tied to neuroscience studies and clinical trials.

What the company does

Cambridge Cognition provides cognitive testing and data services, including its CANTAB digital cognitive assessment platform, used in Clinical Trials and increasingly in healthcare and consumer wellness settings. Its customers include pharmaceutical and academic organisations running studies in brain health.

The Alzheimer's partnership

On 21 September the company announced a partnership with C2N Diagnostics and The Alzheimer's Trust to build an integrated diagnostic pathway for Alzheimer's disease in the UK, aiming at earlier and more accurate diagnosis. The pathway combines C2N's PrecivityAD2 blood test, Cambridge Cognition's CANTAB Pathway platform and the trust's blood-draw and MRI infrastructure. The announcement cited studies suggesting that the combined approach detects the disease with about 90% accuracy, compared with about 70% for standard GP assessment. It framed the project as a response to diagnostic delays in the UK.

On 6 October LSE:COG said it had joined an NHS study led by Imperial College. A director share purchase was announced on 23 September.

Interim results

Results for the six months to 30 June 2026, published on 16 September, showed revenue of about 5.0 million pounds, up 16%, of which around 0.1 million pounds came from new healthcare and consumer wellness pilots. The company remained loss-making at the adjusted EBITDA level, but the loss narrowed to about 0.3 million pounds. Operating Cash Flow was positive, and the company ended the period with about 0.6 million pounds of cash and no Debt after repaying borrowings.

New sales orders were about 6.0 million pounds, and the order book stood at about 16.1 million pounds. Management expects full-year revenue of at least 10.0 million pounds, although about 0.7 million pounds of contracted revenue has been rescheduled.

Fundraising

A 2.6 million pound fundraise was completed in July 2026 to fund Investment programmes for growth. A result of retail offer announcement was made on 30 June, and a general meeting result and director dealing notice followed on 10 July. Several major holding notifications were filed in July, and a trading update was published on 27 July.

Sector and index context

Digital cognitive assessment sits where clinical studies, healthcare and consumer technology meet. Recent attention on blood tests and treatments for Alzheimer's has raised Demand for tools that identify patients early, and Cambridge Cognition (LSE:COG) is positioning its platform for that opening. AIM hosts a number of small life sciences and digital health businesses, and many rely on periodic fundraisings.

Key risks

The company has a thin cash balance relative to its size, so the July fundraising and operating cash flow matter. Revenue depends heavily on pharmaceutical trial activity, which can be delayed, as the rescheduled 0.7 million pounds of contracted revenue illustrates. New healthcare and consumer markets are early-stage and unproven, and the partnership's accuracy claims rest on cited studies rather than the pathway's own results.

What to watch next

The key signals will be the delivery of at least 10.0 million pounds of revenue for the year, conversion of the 16.1 million pound order book, and any progress from the healthcare pilots. LSE:COG's full-year trading update and the early results from the NHS and Alzheimer's pathway work will show whether the new markets can add meaningful revenue.